Wealthcare Advisory Partners LLC Buys New Shares in Guardant Health, Inc. (NASDAQ:GH)

Wealthcare Advisory Partners LLC purchased a new stake in shares of Guardant Health, Inc. (NASDAQ:GH) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 8,255 shares of the company’s stock, valued at approximately $252,000.

Several other large investors have also recently added to or reduced their stakes in GH. Wellington Management Group LLP boosted its position in shares of Guardant Health by 188.6% during the 3rd quarter. Wellington Management Group LLP now owns 10,127,528 shares of the company’s stock valued at $232,325,000 after acquiring an additional 6,618,785 shares in the last quarter. Eventide Asset Management LLC lifted its stake in Guardant Health by 2.0% during the third quarter. Eventide Asset Management LLC now owns 3,837,300 shares of the company’s stock worth $88,028,000 after purchasing an additional 76,762 shares during the period. Geode Capital Management LLC boosted its holdings in Guardant Health by 1.1% during the third quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company’s stock valued at $64,754,000 after purchasing an additional 29,686 shares in the last quarter. ARK Investment Management LLC grew its stake in shares of Guardant Health by 233.5% in the 3rd quarter. ARK Investment Management LLC now owns 1,512,694 shares of the company’s stock valued at $34,701,000 after purchasing an additional 1,059,104 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Guardant Health by 1,282.5% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,226,176 shares of the company’s stock worth $28,128,000 after buying an additional 1,137,482 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on GH. JPMorgan Chase & Co. lifted their price target on shares of Guardant Health from $48.00 to $50.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Sanford C. Bernstein reduced their target price on Guardant Health from $40.00 to $35.00 and set an “outperform” rating on the stock in a report on Wednesday, October 30th. Leerink Partners dropped their price target on Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Finally, The Goldman Sachs Group boosted their price objective on Guardant Health from $32.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Fifteen analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $40.60.

Guardant Health Trading Up 23.1 %

GH stock opened at $45.13 on Wednesday. The stock has a 50-day moving average price of $34.21 and a two-hundred day moving average price of $29.13. Guardant Health, Inc. has a 1 year low of $15.81 and a 1 year high of $45.68. The stock has a market cap of $5.58 billion, a PE ratio of -10.64 and a beta of 1.28.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.33). The business had revenue of $191.48 million for the quarter, compared to the consensus estimate of $170.49 million. Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. Guardant Health’s revenue was up 33.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.73) earnings per share. On average, analysts forecast that Guardant Health, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Musa Tariq sold 2,320 shares of Guardant Health stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $35.00, for a total transaction of $81,200.00. Following the completion of the sale, the director now directly owns 2,676 shares of the company’s stock, valued at approximately $93,660. This trade represents a 46.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Meghan V. Joyce sold 2,896 shares of the company’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total transaction of $86,590.40. Following the completion of the transaction, the director now owns 7,648 shares in the company, valued at $228,675.20. This trade represents a 27.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,548 shares of company stock valued at $179,782. 5.50% of the stock is owned by insiders.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.